Clinical Characteristics and Prognostic Analysis of Newly Diagnosed Acute Myeloid Leukemia Patients with NRAS and KRAS Gene Mutations.
10.19746/j.cnki.issn.1009-2137.2025.03.009
- Author:
Zhang-Yu YU
1
;
Bo CAI
1
;
Yi WANG
1
;
Yang-Yang LEI
1
;
Bing-Xia LI
1
;
Yu-Fang LI
1
;
Yan-Ping SHI
1
;
Jia-Xin CHEN
1
;
Shu-Hong LIU
1
;
Chang-Lin YU
1
;
Mei GUO
1
Author Information
1. Department of Hematology, The Fifth Medical Center of the Chinese PLA General Hospital, Beijing 100071, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia
- MeSH:
Humans;
Leukemia, Myeloid, Acute/diagnosis*;
Mutation;
Prognosis;
Proto-Oncogene Proteins p21(ras)/genetics*;
GTP Phosphohydrolases/genetics*;
Retrospective Studies;
Membrane Proteins/genetics*;
Female;
Male;
Middle Aged;
Adult;
Aged
- From:
Journal of Experimental Hematology
2025;33(3):682-690
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To retrospectively analyze the clinical characteristics, co-mutated genes in newly diagnosed acute myeloid leukemia (AML) patients with NRAS and KRAS gene mutations, and the impact of NRAS and KRAS mutations on prognosis.
METHODS:The clinical data and next-generation sequencing results of 80 newly diagnosed AML patients treated at our hospital from December 2018 to December 2023 were collected. The clinical characteristics, co-mutated genes of NRAS and KRAS , and the impact of NRAS and KRAS mutations on prognosis in newly diagnosed AML patients were analyzed.
RESULTS:Among 80 newly diagnosed AML patients, NRAS mutations were detected in 20 cases(25.0%), and KRAS mutations were detected in 9 cases(11.3%). NRAS mutations predominantly occurred at codons 12 and 13 of exon 2, as well as codon 61 of exon 3, while KRAS mutations were most commonly occurred at codons 12 and 13 of exon 2, all of which were missense mutations. There were no statistically significant differences observed in terms of age, sex, white blood cell count(WBC), hemoglobin(Hb), platelet count(PLT), bone marrow blasts, first induction chemotherapy regimen, CR1/CRi1 rates, chromosome karyotype, 2022 ELN risk classification and allogeneic hematopoietic stem cell transplantation(allo-HSCT) among the NRAS mutation group, KRAS mutation group and NRAS/KRAS wild-type group (P >0.05). KRAS mutations were significantly correlated with PTPN11 mutations (r =0.344), whereas no genes significantly associated with NRAS mutations were found. Survival analysis showed that compared to the NRAS/KRAS wild-type group, patients with NRAS mutation had a relatively higher 5-year overall survival (OS) rate and relapse-free survival (RFS) rate, though the differences were not statistically significant (P =0.097, P =0.249). Compared to the NRAS/KRAS wild-type group, patients with KRAS mutation had a lower 5-year OS rate and RFS rate, with no significant differences observed (P =0.275, P =0.442). There was no significant difference in the 5-year RFS rate between the KRAS mutation group and NRAS mutation group (P =0.157), but the 5-year OS rate of patients with KRAS mutation was significantly lower than that of patients with NRAS mutation (P =0.037).
CONCLUSION:In newly diagnosed AML patients, KRAS mutation was significantly correlated with PTPN11 mutation. Compared to patients with NRAS/KRAS wild-type, those with NRAS mutation showed a more favorable prognosis, while patients with KRAS mutation showed a poorer prognosis; however, these differences did not reach statistical significance. Notably, the prognosis of AML patients with KRAS mutation was significantly inferior compared to those with NRAS mutation.
